Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis [0.03%]
奥密克戎流行期间癌症相关延误、患者疫苗接种状态和冠状病毒疾病2019预后的简短报告：TERAVOLT分析简报
Christine M Bestvina,Jennifer G Whisenant,Valter Torri et al.
Christine M Bestvina et al.
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 s...
Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC-Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy [0.03%]
含替加氟尿嘧啶辅助化疗用于完全切除的淋巴结阴性非小细胞肺癌患者疗效的真实世界数据：分子靶向药物和免疫治疗时代
Takehito Shukuya,Kazuya Takamochi,Hiroyuki Sakurai et al.
Takehito Shukuya et al.
Introduction: In Japan, adjuvant tegafur-uracil (UFT) chemotherapy is recommended for patients with completely resected, stage I NSCLC. This treatment requires real-world re-evaluation because of recent advances in target...
Suzanne Wait,Arturo Alvarez-Rosete,Tasnime Osama et al.
Suzanne Wait et al.
Lung cancer is the leading cause of cancer death in Europe. Screening by means of low-dose computed tomography (LDCT) can shift detection to an earlier stage and reduce lung cancer mortality in high-risk individuals. However, to date, Polan...
Surbhi Singhal,Jessica Hellyer,Madhu M Ouseph et al.
Surbhi Singhal et al.
Introduction: Paraneoplastic autoimmune diseases (ADs) are a hallmark of thymic epithelial tumors (TETs) and affect treatment management in patients with advanced-stage tumors, yet the risk factors for development of AD i...
Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC [0.03%]
Dabrafenib联合Trametinib与真实世界标准治疗BRAF突变晚期非小细胞肺癌的临床疗效对比：Ⅱ期临床试验结果
Bruce E Johnson,Christina S Baik,Julien Mazieres et al.
Bruce E Johnson et al.
Introduction: BRAF mutations are rare in patients with NSCLC, and treatment options are limited. Dabrafenib plus trametinib (dab-tram) was approved for BRAFV600-mutated advanced NSCLC (aNSCLC), based on results from a pha...
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC [0.03%]
I期非小细胞肺癌的预后判断指标是肿瘤有无磨玻璃成分而不是低剂量CT检出的肿瘤大小
Akira Hamada,Kenichi Suda,Toshio Fujino et al.
Akira Hamada et al.
Introduction: Recent studies have suggested that including presence or absence of ground-glass opacity (GGO) may improve the tumor descriptor (T descriptor) classification in clinical stage I NSCLC. In this study, we anal...
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer [0.03%]
肺癌临床分期评估中脑部影像学检查指征的再思考
Matthew D Pichert,Maureen E Canavan,Richard C Maduka et al.
Matthew D Pichert et al.
Introduction: Available guidelines are inconsistent as to whether patients with newly diagnosed clinical stage II NSCLC should receive routine brain imaging. ...
The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review [0.03%]
程序性死亡配体-1在恶性胸膜间皮瘤中的预测和预后价值：系统文献回顾
Aaron S Mansfield,Rebecca J Brown,Cormac Sammon et al.
Aaron S Mansfield et al.
Introduction: Given the emergence of combination of programmed cell death protein-1 and CTLA4 pathway blockade as effective treatment options in malignant pleural mesothelioma (MPM), there is interest in the extent to whi...
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis [0.03%]
一线治疗亚洲患者表皮生长因子受体突变（19号del和L858R）晚期非小细胞肺癌的总生存期优势：系统评价和网络 meta 分析
Sik-Kwan Chan,Horace Cheuk-Wai Choi,Victor Ho-Fun Lee
Sik-Kwan Chan
Introduction: Randomized controlled trials have investigated different first-line treatments for patients with advanced EGFR-mutated NSCLC. Nevertheless, their efficacy, in particular, the long-term overall survival (OS) ...
The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma [0.03%]
真实世界证据在恶性胸膜间皮瘤治疗选择中的作用
Paul Wheatley-Price,Sara Moore,Christopher W Lee
Paul Wheatley-Price